ULISSE BIOMED SPA (UBM.MI) Fundamental Analysis & Valuation

BIT:UBM • IT0005451213

Current stock price

0.8 EUR
0 (0%)
Last:

This UBM.MI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. UBM.MI Profitability Analysis

1.1 Basic Checks

  • In the past year UBM has reported negative net income.
  • UBM had a negative operating cash flow in the past year.
  • UBM had negative earnings in 4 of the past 5 years.
  • In the past 5 years UBM always reported negative operating cash flow.
UBM.MI Yearly Net Income VS EBIT VS OCF VS FCFUBM.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 -2M -4M

1.2 Ratios

  • With a Return On Assets value of -21.16%, UBM perfoms like the industry average, outperforming 51.81% of the companies in the same industry.
  • With a decent Return On Equity value of -24.96%, UBM is doing good in the industry, outperforming 62.65% of the companies in the same industry.
Industry RankSector Rank
ROA -21.16%
ROE -24.96%
ROIC N/A
ROA(3y)-18.88%
ROA(5y)-10.46%
ROE(3y)-21.54%
ROE(5y)-11.74%
ROIC(3y)N/A
ROIC(5y)N/A
UBM.MI Yearly ROA, ROE, ROICUBM.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for UBM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
UBM.MI Yearly Profit, Operating, Gross MarginsUBM.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. UBM.MI Health Analysis

2.1 Basic Checks

  • UBM does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • UBM has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for UBM has been increased compared to 5 years ago.
  • The debt/assets ratio for UBM has been reduced compared to a year ago.
UBM.MI Yearly Shares OutstandingUBM.MI Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
UBM.MI Yearly Total Debt VS Total AssetsUBM.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

  • UBM has an Altman-Z score of 1.57. This is a bad value and indicates that UBM is not financially healthy and even has some risk of bankruptcy.
  • UBM's Altman-Z score of 1.57 is fine compared to the rest of the industry. UBM outperforms 65.06% of its industry peers.
  • A Debt/Equity ratio of 0.05 indicates that UBM is not too dependend on debt financing.
  • UBM has a Debt to Equity ratio of 0.05. This is in the better half of the industry: UBM outperforms 67.47% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Altman-Z 1.57
ROIC/WACCN/A
WACC8%
UBM.MI Yearly LT Debt VS Equity VS FCFUBM.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 10M 20M

2.3 Liquidity

  • UBM has a Current Ratio of 2.15. This indicates that UBM is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 2.15, UBM is in line with its industry, outperforming 42.17% of the companies in the same industry.
  • A Quick Ratio of 1.07 indicates that UBM should not have too much problems paying its short term obligations.
  • UBM's Quick ratio of 1.07 is on the low side compared to the rest of the industry. UBM is outperformed by 67.47% of its industry peers.
Industry RankSector Rank
Current Ratio 2.15
Quick Ratio 1.07
UBM.MI Yearly Current Assets VS Current LiabilitesUBM.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. UBM.MI Growth Analysis

3.1 Past

  • UBM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 65.69%, which is quite impressive.
  • The Revenue has grown by 119.93% in the past year. This is a very strong growth!
  • The Revenue has been growing by 135.06% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)65.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%29.47%
Revenue 1Y (TTM)119.93%
Revenue growth 3Y40.55%
Revenue growth 5Y135.06%
Sales Q2Q%42.57%

3.2 Future

  • Based on estimates for the next years, UBM will show a very strong growth in Earnings Per Share. The EPS will grow by 26.08% on average per year.
  • Based on estimates for the next years, UBM will show a very strong growth in Revenue. The Revenue will grow by 59.01% on average per year.
EPS Next Y84.6%
EPS Next 2Y36.32%
EPS Next 3Y26.08%
EPS Next 5YN/A
Revenue Next Year-19.59%
Revenue Next 2Y26.82%
Revenue Next 3Y59.01%
Revenue Next 5YN/A

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
UBM.MI Yearly Revenue VS EstimatesUBM.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 1M 2M 3M 4M 5M
UBM.MI Yearly EPS VS EstimatesUBM.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 0 -0.01 -0.02 -0.03

More info and screens

Find the best growth stocksShow best growing peers

1

4. UBM.MI Valuation Analysis

4.1 Price/Earnings Ratio

  • UBM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for UBM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
UBM.MI Price Earnings VS Forward Price EarningsUBM.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
UBM.MI Per share dataUBM.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6 0.8

4.3 Compensation for Growth

  • UBM's earnings are expected to grow with 26.08% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.32%
EPS Next 3Y26.08%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. UBM.MI Dividend Analysis

5.1 Amount

  • No dividends for UBM!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

UBM.MI Fundamentals: All Metrics, Ratios and Statistics

ULISSE BIOMED SPA

BIT:UBM (12/8/2025, 7:00:00 PM)

0.8

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A
Earnings (Next)N/A
Inst Owners0.58%
Inst Owner ChangeN/A
Ins Owners33.36%
Ins Owner ChangeN/A
Market Cap20.41M
Revenue(TTM)925.90K
Net Income(TTM)-5.30M
Analysts84
Price Target1.52 (90%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)20.65%
PT rev (3m)36.7%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)9.76%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 22.04
P/FCF N/A
P/OCF N/A
P/B 0.96
P/tB 7.09
EV/EBITDA N/A
EPS(TTM)-0.2
EYN/A
EPS(NY)-0.03
Fwd EYN/A
FCF(TTM)-0.11
FCFYN/A
OCF(TTM)-0.1
OCFYN/A
SpS0.04
BVpS0.83
TBVpS0.11
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -21.16%
ROE -24.96%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-18.88%
ROA(5y)-10.46%
ROE(3y)-21.54%
ROE(5y)-11.74%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 3.07%
Cap/Sales 10.07%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.15
Quick Ratio 1.07
Altman-Z 1.57
F-Score5
WACC8%
ROIC/WACCN/A
Cap/Depr(3y)25.49%
Cap/Depr(5y)134.9%
Cap/Sales(3y)106.09%
Cap/Sales(5y)137.8%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)65.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%29.47%
EPS Next Y84.6%
EPS Next 2Y36.32%
EPS Next 3Y26.08%
EPS Next 5YN/A
Revenue 1Y (TTM)119.93%
Revenue growth 3Y40.55%
Revenue growth 5Y135.06%
Sales Q2Q%42.57%
Revenue Next Year-19.59%
Revenue Next 2Y26.82%
Revenue Next 3Y59.01%
Revenue Next 5YN/A
EBIT growth 1Y23.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year80.83%
EBIT Next 3Y25.99%
EBIT Next 5YN/A
FCF growth 1Y-78.81%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-89.7%
OCF growth 3YN/A
OCF growth 5YN/A

ULISSE BIOMED SPA / UBM.MI Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for ULISSE BIOMED SPA?

ChartMill assigns a fundamental rating of 3 / 10 to UBM.MI.


Can you provide the valuation status for ULISSE BIOMED SPA?

ChartMill assigns a valuation rating of 1 / 10 to ULISSE BIOMED SPA (UBM.MI). This can be considered as Overvalued.


What is the profitability of UBM stock?

ULISSE BIOMED SPA (UBM.MI) has a profitability rating of 1 / 10.


What is the financial health of ULISSE BIOMED SPA (UBM.MI) stock?

The financial health rating of ULISSE BIOMED SPA (UBM.MI) is 3 / 10.